Patents Assigned to ZyStor Therapeutics, Inc.
-
Publication number: 20110223147Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: May 7, 2009Publication date: September 15, 2011Applicant: ZYSTOR THERAPEUTICS, INC.Inventors: Jonathan H. Lebowitz, John Maga
-
Patent number: 7858576Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: May 30, 2007Date of Patent: December 28, 2010Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Patent number: 7785856Abstract: Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: September 12, 2007Date of Patent: August 31, 2010Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20100075906Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: November 2, 2009Publication date: March 25, 2010Applicant: Zystor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Patent number: 7629309Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: November 3, 2004Date of Patent: December 8, 2009Assignee: Zystor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Publication number: 20090203575Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: February 19, 2009Publication date: August 13, 2009Applicant: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Patent number: 7560424Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: October 16, 2002Date of Patent: July 14, 2009Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Publication number: 20090029467Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: May 30, 2007Publication date: January 29, 2009Applicant: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Publication number: 20080299640Abstract: Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: September 12, 2007Publication date: December 4, 2008Applicant: ZyStor Therapeutics, Inc.Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20080241118Abstract: Disclosed are methods and compositions for targeting therapeutic proteins to the brain. Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain. Soluble fusion proteins that include an IGF targeting moiety are transported to neural tissue in the brain from blood. Methods and compositions of the invention include therapeutic applications for treating lysosomal storage diseases. The invention also provides nucleic acids and cells for expressing IGF fusion proteins.Type: ApplicationFiled: February 19, 2008Publication date: October 2, 2008Applicant: ZyStor Therapeutics, Inc.Inventor: Jonathan LeBowitz
-
Patent number: 7396811Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: April 30, 2002Date of Patent: July 8, 2008Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Publication number: 20060121018Abstract: Disclosed are methods and compositions for targeting therapeutic proteins to the brain. Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain. Soluble fusion proteins that include an IGF targeting moiety are transported to neural tissue in the brain from blood. Methods and compositions of the invention include therapeutic applications for treating lysosomal storage diseases. The invention also provides nucleic acids and cells for expressing IGF fusion proteins.Type: ApplicationFiled: September 23, 2005Publication date: June 8, 2006Applicant: ZyStor Therapeutics, Inc.Inventor: Jonathan LeBowitz
-
Publication number: 20050244400Abstract: Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: February 10, 2005Publication date: November 3, 2005Applicant: ZyStor Therapeutics, Inc.Inventors: Jonathan LeBowitz, John Maga